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Abstract
Background: Oral squamous cell carcinoma (OSCC) is one of the common malignancies in Southeast Asia.
Epigenetic changes, mainly the altered DNA methylation, have been implicated in many cancers. Considering the
varied environmental and genotoxic exposures among the Indian population, we conducted a genome-wide DNA
methylation study on paired tumor and adjacent normal tissues of ten well-differentiated OSCC patients and
validated in an additional 53 well-differentiated OSCC and adjacent normal samples.
Results: Genome-wide DNA methylation analysis identified several novel differentially methylated regions
associated with OSCC. Hypermethylation is primarily enriched in the CpG-rich regions, while hypomethylation is
mainly in the open sea. Distinct epigenetic drifts for hypo- and hypermethylation across CpG islands suggested
independent mechanisms of hypo- and hypermethylation in OSCC development. Aberrant DNA methylation in the
promoter regions are concomitant with gene expression. Hypomethylation of immune genes reflect the
lymphocyte infiltration into the tumor microenvironment. Comparison of methylome data with 312 TCGA HNSCC
samples identified a unique set of hypomethylated promoters among the OSCC patients in India. Pathway analysis
of unique hypomethylated promoters indicated that the OSCC patients in India induce an anti-tumor T cell
response, with mobilization of T lymphocytes in the neoplastic environment. Survival analysis of these
epigenetically regulated immune genes suggested their prominent role in OSCC progression.
Conclusions: Our study identified a unique set of hypomethylated regions, enriched in the promoters of immune
response genes, and indicated the presence of a strong immune component in the tumor microenvironment.
These methylation changes may serve as potential molecular markers to define risk and to monitor the prognosis
of OSCC patients in India.
Keywords: Oral squamous cell carcinoma, CTLA4, CpG island, Differentially methylated regions, Methylation-specific
PCR, Bisulfite cloning and sequencing, Gene expression
* Correspondence: rchatterjee@isical.ac.in
†Equal contributors
1Human Genetics Unit, Indian Statistical Institute, 203 B. T. Road, Kolkata
700108, India
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Basu et al. Clinical Epigenetics  (2017) 9:13 
DOI 10.1186/s13148-017-0314-x
Background
Oral cancer consists of any malignant neoplasm in the
lip, floor of the mouth, buccal mucosa, gingiva, retromo-
lar trigone, palate, or in the tongue and is the most com-
mon form of cancer in the head and neck squamous cell
cancer (HNSCC) category. It is the 11th most common
cancer worldwide with an estimated 300,400 new cases
and 145,400 deaths occurred in 2012 worldwide [1]. Glo-
bally, India has the highest incidence of oral cancer per
year and is the leading cancer among Indian men and
fifth most common among women [2, 3]. Most oral ma-
lignancies occur as squamous cell carcinomas (SCCs),
and many OSCCs develop from premalignant conditions
of the oral cavity [4]. A wide array of conditions have
been implicated in the development of oral cancer, in-
cluding leukoplakia, erythroplakia, palatal lesion of re-
verse cigar smoking, oral lichen planus, oral submucous
fibrosis, discoid lupus erythematosus, and hereditary dis-
orders such as dyskeratosis congenital and epidermolysis
bullosa [5]. Despite the general accessibility of the oral
cavity during physical examination, many malignancies
are not diagnosed until late stages of the disease. The
major risk factors for oral cavity cancer are smoking,
smokeless tobacco, alcohol, and HPV infection [1]. The
higher incidence of oral cancer in India, Taiwan, and
other neighboring countries is attributed to popularity of
different oral habits like chewing smokeless tobacco,
betel quid, and areca nut [1].
Oral cancer is a multifactorial disease involving gen-
etic and epigenetic abnormalities. The addition of a
methyl group at the cytosine residue of CpG di-
nucleotide have a profound effect on initiation and
progression of cancer [6–9]. Hypermethylation of
CpG islands (CGIs) in the promoter region results in
transcriptional silencing of tumor suppressor genes,
whereas hypomethylation leads to oncogene activation
in many cancers [7–10]. As DNA methylation alteration
often occurs early in cancer development, candidate
methylation markers may be valuable for early and specific
cancer detection [11–13]. Promoter hypermethylation-
mediated silencing of different classes of genes involved in
cell-cycle regulation, signaling pathways, angiogenesis,
proliferation, differentiation, DNA repair, and apoptosis
are reported in OSCC [13–22].
Studies have indicated involvement of genetic, epigen-
etic, and oral habits in the development of oral cancer.
The contribution of the varied risk factors in the Indian
subcontinent may lead to a distinct disease pathogenesis.
The mechanisms by which different habits influence
phenotype and disease risk may involve the altered epi-
genetic regulation of genes. Recently, candidate gene-
specific studies identified epigenetic modifications in the
promoter regions of OSCC patients in India. P16, DAPK,
and MGMT gene promoter hypermethylation was
reported in oral cancer tissues compared to correspond-
ing adjacent normal mucosa [23]. EDNRB, KIF1A, DCC,
P16, P15, hMLH1, MGMT, and E-cadherin gene pro-
moter hypermethylation is also observed in Indian
OSCC patients [24, 25]. Studies with esophageal cancer
patients from North Eastern Indians have shown that
tobacco consumption possibly interacts with carcinogen-
metabolizing genes and modulate the promoter hyper-
methylations of tumor suppressor genes [26]. However,
most of these studies focused on cancer-associated
hypermethylation at specific genes. Surprisingly, OSCC-
associated DNA hypomethylation received little atten-
tion. Furthermore, global hypomethylation observed in
OSCC have not been characterized profoundly among
Indian patients.
High throughput genome-wide methylation study pro-
vides a comprehensive platform to understand the over-
view of DNA methylation [27]. Genome-wide DNA
methylation profiles in the OSCC patients of this region
thus may help us to understand the disease pathogen-
esis. However, to date, there is no systematic genome-
wide study to investigate whether changes in DNA
methylation can influence the OSCC development
among the patients in India. In the present study, we
have determined the global methylation status of well-
differentiated OSCC and adjacent normal tissues using
Illumina Infinium 450K BeadChip Array. Differentially
methylated regions were validated in another cohort of
OSCC patients in India. Gene expression profiles of
some of these aberrantly methylated genes showed in-
verse correlation with the promoter methylation. A com-
parative analysis of the methylome data of these OSCC
patients with the available TCGA HNSC patients identi-
fied some novel genes, which showed exclusive differen-
tial methylation in OSCC patients of Indian population.
Survivability analysis suggested prognostic significance
of some of these genes in OSCC.
Results
Genome-wide DNA methylation distribution in the well-
differentiated OSCC
We have determined the genome-wide DNA methylation
profiles of OSCC patients using the Illumina Infinium
450K array. In total, 64 OSCC patients were recruited for
the study (Table 1, Additional file 1: Table S1). All tissue
samples were histopathologically verified and diagnosed to
be well-differentiated OSCC. Ten pairs of cancer and adja-
cent normal tissues and one unpaired cancer tissue from
the buccal mucosa of OSCC patients were used for the
global methylome analysis. To avoid the influence of DNA
methylation on X chromosome inactivation, we consid-
ered only the autosomal probes for further analysis.
Probes showing |Δβ| ≥0.20 between the cancer and adja-
cent normal tissues with adjusted P value ≤0.05 were
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defined as differentially methylated probes (DMPs). Fol-
lowing the criteria, we identified 21,810 DMPs including
16,140 hypomethylated and 5670 hypermethylated probes.
Hierarchical clustering of top 2000 DMPs showed separ-
ate clustering of OSCC and adjacent normal tissues
(Fig. 1a), except for two normal samples which clustered
with disease group. This might be due to hyperplastic to
mild dysplastic cells, as noticed in the histopathology of
these samples (Additional file 2: Figure S1A–G). However,
no distinct clustering was observed between HPV-positive
and HPV-negative samples. Separate comparison between
HPV-positive and HPV-negative samples could not iden-
tify any probe that was significantly differentially methyl-
ated according to our criterion |Δβ| ≥0.20 and adjusted P
value ≤0.05.
Next, we sought to determine the enrichment of
21,810 DMPs at CpG islands (CGIs) and non-CGI re-
gions of the genome (Additional file 2: Figure S2A, B).
Enrichment of hyper- and hypomethylated probes were
significantly different between the CGIs and non-CGI
regions (Additional file 2: Figure S2A, B). Approxi-
mately, 85% of the DMPs were in the non-CGI, and ma-
jority (82%) of these probes are hypomethylated. On the
contrary, majority of the CGI-overlapped DMPs (70%)
are hypermethylated (Additional file 2: Figure S2A, B).
Further classification of these DMPs based on their en-
richment at CGIs, shores, shelves, and open sea clearly
showed that majority of the hypermethylated probes
(72%, i.e., 4082 DMPs) were enriched in the CGIs,
shores, and shelves, whereas hypomethylated probes
(67%) were mostly enriched in the open sea (Fig. 1b). To
determine the genomic localization of these probes, we
mapped these DMPs into the promoters, exons, introns,
repeat regions, and other regions (Additional file 2:
Figure S2C, D). Complying with the previous observa-
tions, we found that the CGI-overlapped DMPs were
mostly hypermethylated and the non-CGI DMPs were
mostly hypomethylated irrespective of their genomic lo-
calizations. The pattern of differential methylation across
the CGIs, shores, and shelves showed contrasting char-
acteristics between hypomethylated and hypermethy-
lated regions. The hypermethylation of the CpGs were
specifically localized to the CGIs (P value ≤0.0001), while
shores and shelves did not show any significant differen-
tial methylation (P value ≥0.05). On the contrary, signifi-
cant hypomethylation (P value ≤0.05) was observed
across CGIs, shores, and shelves between tumors and
adjacent normal tissues, suggesting different mecha-
nisms of hypo- and hypermethylation in OSCC develop-
ment (Fig. 1c). The hierarchical clustering of average β
values for the promoter and the CGIs also indicated the
distinct epigenetic regulations between the well-
differentiated OSCC and adjacent normal tissues (Add-
itional file 2: Figure S3A, B).
Validation of differentially methylated promoters
In order to validate the 450K array results, we deter-
mined the methylation status of five randomly selected
differentially methylated promoters by sequencing the
cloned bisulfite-converted DNA samples of OSCC and
adjacent normal tissues (Fig. 2a, b, Additional file 2: Fig-
ure S4). Clonal validation showed hypermethylation for
the HLA-DPB1 (12 to 81%), LDLRAD4 (0 to 38%), LHX1
(34 to 98%), and LXN (2 to 29%) promoters and hypo-
methylation for PTPN22 (86 to 30%) in tumors com-
pared to adjacent normal tissues. These results were
consistent with that of the 450K array data. Further-
more, a panel of 14 differentially methylated promoters
were selected for validation in additional 53 pairs of
tumor and adjacent normal tissues using methylation-
specific quantitative real-time PCR (qMSP) (Table 2).
Most of the differentially methylated promoters showed
60 to 90% concordance with the results obtained from
the genome-wide methylation data. Some of the discord-
ant results can also be attributed to the hyperplastic or
dysplastic tissue morphology on some of the adjacent
normal samples.
Transcriptional effects of aberrant DNA methylation
To investigate the transcriptional regulation of differen-
tially methylated promoters in OSCC compared to adja-
cent normal tissues, we studied gene expression profile
of 14 differentially methylated genes identified from the
discovery cohort (Fig. 2c, d, Additional file 2: Figure S5,
6). These included seven genes with hypermethylated
promoters, namely, LXN, ZNF154, ZNF577, ZSCAN31,
CTDSP1, LDLRAD4, and HLA-DPB1, and seven with
hypomethylated promoters, including PTPN22, RUNX1,
Table 1 Demographic and clinical characteristics of the discovery
and validation set
Characteristics Patient information
Discovery set Validation set
Total patients 11 53
Normal/disease 10/11 53/53
Age range (in years) 40–90 27–78
Mean age (SD) (in years) 51.37 (14.33) 53.50 (12.45)
No. of males/females 7/4 39/14
HPV: positive/negative 6/5 29/24
Oral habits
Smoking tobacco 1 2
Chewing tobacco 2 22
Other habits 1 1
Multiple habits 4 10
No habits 2 18
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IL6, CD28, TLR1, CD80, CD22, and TNFa. Genes with
hypermethylated promoters such as LXN (P value = 2.94 ×
10−2), ZNF154 (P value = 3.10 × 10−2), CTDSP1 (P value =
2.40 × 10−2), and ZNF577 (P value = 1.80 × 10−3) showed
significant downregulation in OSCC tissues compared to
the adjacent normal tissues (Fig. 2c, d, Additional file 2:
Figure S5). ZSCAN31 and LDLRAD4 showed downregula-
tion but did not reach the level of significance at 0.05. Only,
HLA-DPB1 showed significant upregulation (P value =
3.80 × 10−2) in spite of its promoter getting hypermethy-
lated. A closer look into the methylation data showed
hypomethylation at the promoter region of another isoform
of the HLA-DPB1 gene, which may be the reason for this
discordant expression profile. Similarly, significant upregu-
lations were observed for the hypomethylated genes
PTPN22 (P value = 5.9 × 10−3), RUNX1 (P value = 4.5 × 10
−3), IL6 (P value = 1.56 × 10−2), CD28 (P value = 7.5 × 10−3),
TLR1 (P value = 2.63 × 10−2), CD80 (P value = 3.34 × 10−5),
and TNFa (P value = 9.8 × 10−3) (Fig. 2d, Additional file 2:
Figure S6). The gene expression analysis was consistent
with methylation status and further showed the influence




Fig. 1 Distribution of differentially methylated probes (DMPs). a Heatmap of top 2000 DMPs. Hierarchical clustering showing separate grouping
of DMPs for OSCC and adjacent normal tissue. b Genomic localisation of hypermethylated and hypomethylated probes at the CpG islands (CGIs),
shore, shelves, and open sea. c Average methylation across the CGIs, shores, and shelves for hypo- and hypermethylated CGIs
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transcriptional activity of the genes. This also strengthened
the validity of the differentially methylated genes identified
in our discovery cohort.
Comparison of methylation changes with TCGA data
We compared the genome-wide DNA methylation data
of the OSCC patients in India with that of the available
TCGA HNSC samples (https://tcga-data.nci.nih.gov/
docs/publications/tcga/?). We only considered 312 sam-
ples at stages 1, 2, 3, and 4A among the 526 publicly
available TCGA HNSC samples (Additional file 3: Table
S2). As we do not have any patients with malignancies
at the larynx, alveolar ridge, oropharynx, and hypophar-
ynx and tonsil carcinoma, remaining 215 TCGA samples
with malignancies at these regions were not included in
our comparative analysis. Hazard ratio was estimated in
Cox model based on the death due to oral cancer by
age, tumor stage, and node involvement. Significant risk
was observed only for the age at the initial pathological
diagnosis of OSCC patients, while tumor stages and
node involvement status showed marginal increased risk
but did not reach the level of significance at 0.05 (Add-
itional file 3: Table S3). Approximately, 92.7% (14,975) of
the hypomethylated and 100% of the hypermethylated
probes had similar methylation pattern, at least with one
stage of the TCGA samples. Interestingly, a subset of dif-
ferentially methylated probes (1165) were uniquely
hypomethylated in tumor tissues of OSCC patients in
India. The methylation profile of these probes were sig-
nificantly different (adjusted P value ≤0.05) from all
stages of the TCGA data (Fig. 3a, Additional file 2:
Figure S7–9). We determined the genomic distribution
A B
C D
Fig. 2 Validation of HumanMethylation450K bead chip data. The upper panel shows the avergae β values, and the lower panel shows the clonal
validation by sequencing the bisulfite-converted products of a LXN and b PTPN22 promoters. The filled circle in the lower panel represents the
methylated, and the open circle represents the unmethylated CpGs. Gene expression of c LXN and d PTPN22 showed significant differential
expression between OSCC and adjacent normal tissues, correlating with methylation status
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of the common and unique DMPs. We observed that
the hypermethylated probes at the CGIs were mainly
enriched at the promoters, while hypomethylated probes
at the CGIs were primarily enriched at the exons and in-
trons (Fig. 3b, Additional file 2: Figure S2B, C). On the
contrary, both hypo- and hypermethyated probes at the
non-CGIs are mostly enriched in the introns. Among
the 1165 unique DMPs, 162 probes overlapped with pro-
moter region of 134 genes. Among these, 40 promoters
were overlapped with CGI, while 94 were non-CGI-
associated promoters. (Additional file 4: Table S4).
Gene ontology enrichment and IPA analysis of
differentially methylated promoters
To determine the functional implication of the common
and unique DMPs, we performed gene ontology analysis.
In total, 21 biological processes have been enriched at
least by 1.5-fold with enrichment P value ≤0.01 for the
common hypermethylated promoters (Additional file 2:
Figure S10). Majority of the enriched biological pro-
cesses are related to regulation of transcription, embry-
onic morphogenesis, cell signaling, transmission of
nerve impulse, and multicellular organismal response to
stress. Among the common hypomethylated promoters,
the major biological processes are mainly related to sen-
sory perception like sensory perception of chemical
stimulus and cognition, inflammatory response, G-
protein-coupled receptors, and metal ion transport.
Twelve biological processes are significantly enriched for
the unique hypomethylated promoters. These are im-
mune response, positive regulation of cytokine biosyn-
thesis, regulation of cell proliferation, T cell activation,
and etc. Enrichment of these immune response genes in-
dicates infiltration of immune cells into the tumor
microenvironment. Our discovery cohort consists of
both HPV-positive and HPV-negative OSCC samples.
We did not find any differential methylation for these
immune genes between OSCC and adjacent normal tis-
sues, suggesting that the unique hypomethylation in
these immune genes are not consequence of HPV infec-
tion. To determine the pathways that may be effected by
the unique hypomethylated promoters, we performed in-
genuity pathway analysis. The top significantly enriched
canonical pathways are the IL9 signaling and CTLA4
signaling in cytotoxic T lymphocytes (Fig. 4). CTLA4 ac-
tivation upon promoter hypomethylation indicates the
negative regulation of effector T cell activation. Overlap-
ping the common hypomethylated promoter with the
CTLA4 signaling pathway suggested preferential binding
of CD86 with CTLA4 than CD28 to negatively regulate
the cytotoxic T cell activation in the neoplastic environ-
ment (Fig. 4b). CD28 promoter is hypomethylated in
both TCGA and OSCC patients in India and found to be
upregulated in the OSCC tissues compared in the adja-
cent normal tissues (Additional file 2: Figure S6D, S8B).
We determined the gene expression profile of both
CD86 and CTLA4 in the OSCC and adjacent normal tis-
sues (Fig. 5). Both CD86 (P value = 6.10 × 10−3) and
CTLA4 (P value = 1.30 × 10−3) showed significant over-
expression in the OSCC tissues compared in the adja-
cent normal tissues, which further validated the
epigenetic regulation of CD86 and CTLA4, specifically
among the OSCC patients in India.
Clinical significance of epigenetically regulated immune
genes
We next focused on the clinical significance of 134
unique differentially methylated genes observed in our
Table 2 Validation of differentially methylated regions
Methylation status in 450K array Overlap with CGI Gene No. of samples No. of concordant samples % of concordant samples
Hypermethylated CGI ZNF577 53 42 79.25
HLA-DPB1 51 38 74.51
LHX1 53 41 77.36
MYH14 13 11 84.62
Non-CGI ZSCAN31 47 35 74.47
LDLRAD4 53 37 69.81
LXN 53 37 69.81
Hypomethylated CGI PIWIL1 14 13 92.86
MFAP2 11 9 81.82
Non-CGI PTPN22 53 33 62.26
SPNS3 14 10 71.43
AIM2 12 10 83.33
SLAMF1 12 8 66.67
SPATA13 10 7 70.00
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study. The survival analysis based on the top 30 unique
DMPs failed to show any significant association with
clinical outcome of the TCGA HNSC patients. However,
expression profile of 17 unique differentially methylated
genes showed significant prognostic relevance in HNSC.
Higher expression of CTLA4 (P value = 4.06 × 10−2),
CCR10 (P value = 8.94 × 10−3), SLAMF1 (P value =
4.85 × 10−3), SLC26A1 (P value = 1.08 × 10−2), TNFRSF4
(P value = 3.90 × 10−4), APOBR (P value = 2.58 × 10−2),
CACNA2D3 (P value = 1.42 × 10−3), CLNK (P value =
4.77 × 10−4), BFSP2 (P value = 8.79 × 10−4), FCRL6 (P
value = 6.14 × 10−3), MFSD7 (P value = 3.52 × 10−2),
P2RY14 (P value = 1.67 × 10−4), TLR9 (P value = 8.75 × 10
−3), and ZAP70 (P value = 1.28 × 10−4) was significantly
correlated with better disease prognosis (Fig. 6,
Additional file 2: Figure S11, 12). On the contrary, low
expression of CAMK2B (P value = 4.42 × 10−2),
MTHFD1L (P value = 2.27 × 10−2), TKT (P value = 3.96 ×
10−2) was significantly associated with better survival
(Fig. 6, Additional file 2: Figure S12). Ten genes, out of
these 14 genes that showed significantly better prognosis
with higher expression, are involved in immune response
pathways (Fig. 6, Additional file 2: Figure S11E, F). The
Kaplan-Meier test based on the gene expression profile
A
B
Fig. 3 Comparison of HumanMethylation450K bead chip with TCGA HNSC samples. a Hierarchical clustering of common hypermethylated,
common hypomethylated, and unique hypomethylated probes in OSCC (D) and adjacent normal samples in India (N), and TCGA normal (TCGA_N)
and HNSC samples for stages 1 (S1), 2 (S2), 3 (S3), and 4A (S4). b Genomic localization at the promoters, exons, introns, repeat regions, and other
regions of common hypomethylated, hypermethylated, and unique hypomethylated probes that are overlapped with CGIs and non-CGIs
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Fig. 4 Ingenuity pathway analysis of uniquely hypomethylated promoters. The most enriched pathways are a IL9 signaling pathway and b CTLA4
signaling in cytotoxic T lymphocytes. Common hypomethylated genes are overlapped with these pathways. Gray-shaded genes are common
hypomethylated, and pink-enclosed genes are with unique hypomethylated promoters
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of CTLA4 showed significantly (P value = 0.007) better
prognosis for the early-stage (stages 1 and 2) patients
when they are overexpressed (Fig. 6), while late-stage
(stages 3 and 4) patients failed to show any significant as-
sociation (P value = 0.53) (Additional file 2: Figure S12G).
Discussion
In this study, we determined the genome-wide methyla-
tion profile of well-differentiated OSCC and adjacent
normal tissues. We identified several novel differentially
methylated regions in oral cancer patients in India.
A total of 21,810 probes were identified to be differen-
tially methylated in well-differentiated squamous cell
carcinoma as compared to adjacent normal tissues. The
analysis followed a stringent cut off of |Δβ| ≥0.2 and
combined P value ≤0.05. DMPs were clustered in two
distinct groups showing a clear difference in methylation
pattern among disease and adjacent normal tissues of
the same patients. Mis-clustering of the two normal
samples were attributed to the hyperplastic to mild dys-
plastic features of these samples. Moreover, one of the
patient was aged 90 years. The age of this patient was
almost an outlier in the discovery set, and it may have
modulated the epigenomic pattern of this patient. We
found 25% of the DMPs were hypermethylated and the
remaining 75% were hypomethylated. As observed in
several cancers, we also found preferential enrichment
of hypermethylated probes in the CpG-rich regions,
while hypomethylated probes were primarily enriched at
the open sea [28]. Interestingly, we have shown that the
epigenetic drift at the CGIs, shores, and shelves were
somewhat different for hyper- and hypomethylated. In
case of hypermethylated promoters, no variation in the
methylation pattern within the shore and shelves were
observed. Only an abrupt and strong enrichment of
hypermethylation in the CGI regions were observed. On
the contrary, hypomethylated promoters showed hypo-
methylation getting spread towards the shore and
shelves. This data suggests that two independent
mechanisms of hypo- and hypermethylation are acting
in OSCC development. It has recently been reported
that the genome-wide hyper- and hypomethylation
patterns are controlled by distinct sets of epigenetic















































Fig. 5 Comparison of uniquely hypomethylated probe between human methylation 450K bead chip and TCGA samples. Methylation status of
unique probes on a CD86 and b CTLA4 promoter in OSCC (disease) and adjacent normal samples (normal) in India and different stages of TCGA
samples (S1, stage 1; S2, stage 2; S3, stage 3; and S4, stage 4A). Methylation profile of these genes in disease tissue of Indian patients was significantly
different from their normal counterpart, as well as from disease stages S1, S2, S3, and S4A of TCGA samples. Gene expression (fold change) of CD86
and CTLA4 showed significantly higher expression in OSCC compared in the adjacent normal tissues among Indian samples. P value ≤0.05 was
considered significant
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simultaneously in two parts of the genome for hypo-
and hypermethylation [29, 30].
Aberrant promoter methylation leading to transcrip-
tional deregulation of a gene are often found in cancers.
In the present study, we focused on the DMPs that over-
lapped with the promoter regions. We have validated a
panel of 14 differentially methylated promoters, identi-
fied from the genome-wide methylation data, in another
cohort of 53 well-differentiated OSCC samples. Most of
the promoter regions have shown methylation pattern
consistent with the array data. We identified several
novel candidate genes that were deregulated due to aber-
rant promoter methylation in OSCC. Differential methy-
lation in promoters as well as altered expression of LXN,
ZNF154, ZNF577, CTDSP1, RUNX1, CD28, and CD80
have not been reported previously in OSCC. LXN mainly
functions as a potential tumor suppressor and reduces
the stem cells transformation into cancer stem cell. It
has previously been shown to be inhibited by promoter
hypermethylation in malignant melanoma, gastric can-
cer, and prostate cancer [31–34]. ZNF154 and ZNF577
downregulation has been reported to be associated with
several cancers [35, 36]. Inhibition of CTDSP family
members promotes the G1/S-phase transition and have
been found to be downregulated in hepatocellular car-
cinoma [37]. Recently, epigenetic regulation of PTPN22
in the esophegal squamous cell carcinoma has been re-
ported [38].We observed distinct hypomethylation of the
PTPN22 promoter in OSCC, which also had inverse cor-
relation with expression pattern of the gene.
Oral cancer is one of the most common malignancies
in India [2]. Environmental exposure to genotoxic agents
such as betel quid, gutkha, chewing tobacco, smoking,
and alcohol have been identified as risk factors towards
the development of oral cancer [39, 40]. Although meth-
anolic extract of Piper betel L. has been reported to have
immunosuppressive effects [41], however, when con-
sumed in combination with areca nut and slaked lime
(betel quid), it can be harmful. Areca nut has been iden-
tified as an independent group I human carcinogen [42].
Areca nut chewed in different forms is predominant
among the peoples of South and Southeast Asian coun-
tries [43]. Pan masala and gutkha, which have very high
concentration of areca nut, have become very popular in
India and Pakistan, especially among adolescents [44, 45].
These genotoxic agents might be acting synergistically
along with the epigenetic machinery towards oral cancer
pathogenesis. Considering the varied exposure to these
populations, we compared the methylation profile of
Indian patients with TCGA HNSC methylation data.
Hypermethylated probes identified in OSCC tissues of
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Fig. 6 Clinical significance of genes associated with uniquely hypomethylated probes. Kaplan-Meier plots of a CTLA4 showed higher gene expression
(high, N = 124) was significantly associated with better disease prognosis than low expression (low, N = 124), while b lower expression of CAMK2B was
associated with better prognosis. c Early-stage patients (stages 1 and 2) showed significantly better prognosis with higher expression of CTLA4. Mantel-
Cox log-rank P values are presented with each survival analysis
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samples. However, we determined a set of hypomethylated
probes that are specific to the Indian patients. Promoter
of some of the carcinogen-metabolizing genes like
CYP8B1 and GSTA3 was found to be hypomethylated,
specifically, in the tumor tissues of OSCC patients in India
(Additional file 4: Table S4). Gene ontology analysis
showed enrichment of immune genes for the hypomethy-
lated promoter in both common and unique clusters.
These data reflects the cell-type composition of the tumor
microenvironment and, in particular, lymphocyte infiltra-
tion in these tumors. A closer look at these genes revealed
that the hypomethylation occurred at promoters of genes
involved in T lymphocytes regulation. Genes encoding
cytotoxic T cell markers, like the CD8 and T cell activation
markers, like CD28, CD80, CD86, ZAP70, PI3 kinase or
the PTPN22 tyrosine phosphatase involved in T cell recep-
tor signaling, and CTLA4 involved in negatively regulating
cytotoxic T cell signaling, are hypomethylated and overex-
pressed in the neoplastic environment. We considered
whole tumor tissues for our DNA methylation analysis.
These tissues are composed of mainly epithelial cells;
however, cells from the surrounding stroma, including fi-
broblasts, extracellular matrix, and immune cells, are also
present in the microenvironment [46]. Hypomethylation
of immune genes in unique and common clusters are
clear indication of infiltration of immune cells into tu-
mors. Ingenuity pathway analysis with the unique differen-
tially methylated promoters revealed enrichment of a
distinct set of genes involved in immune response path-
ways. CTLA4 signaling in cytotoxic T lymphocytes is one
of the most significant pathway enriched by these unique
set of hypomethylated genes. These data indicated that
the OSCC patients in India induce an anti-tumor T cell
response, with mobilization of T lymphocytes in the
tumor microenvironment. This is in accordance with the
different oral habits present among the OSCC patients in
India.
Our study has identified 162 uniquely hypomethylated
probes that mapped to 134 genes, associated with OSCC
patients in India. Survivability analysis showed that ex-
pression of 19 of these genes was significantly correlated
with better disease prognosis. None of these genes have
previously been reported in OSCC. Interestingly, nine
(CCR10, SLAMF1, TNFRSF4, APOBR, CLNK, CTLA4,
FCRL6, P2RY14, and ZAP70) out of these 17 genes are
known to be involved in immune response pathways,
and better disease prognosis was achieved with higher
expression of these genes. Signaling-lymphocytic-
activation-molecule-family1 (SLAMF1) is mainly in-
volved in signal transduction for lymphocyte activation
[47]. Lower expression of SLAMF1 was found to be as-
sociated with unfavorable prognosis in CLL [48]. Tumor
necrosis factor receptor superfamily, member 4
(TNFRSF4) is a co-stimulatory molecule, and agonists of
this molecule have been described to increase anti-
tumor immunity through enhancing T cell response and
suppressing T reg cells [49, 50]. TLR9 on plasmacytoid
dendritic cells are involved in secretion of type I inter-
ferons that are involved in anti-tumor immunity [51].
Interaction of chemokine receptor 10 (CCR10) with its
ligand causes T cell homing and metastasis in melanoma;
higher expression of CCR10 was correlated with lower
survival of glioblastoma patients [52]. ZAP-70 (zeta-
chain (TCR)-associated protein kinase), involved in T
cell activation, was however reported to show poor prog-
nosis in B-CLL with higher expression [53]. Most im-
portantly, we have observed all these genes to be
regulated by hypomethylated regions in promoter that
are unique among OSCC patients in India. Survivability
analysis showed significant prognostic implications of
expression profile of CTLA4 gene involved in negative
regulation of the immune system [54–56]. Higher ex-
pression of the early-stage patients was observed to be
associated with better survival of the patients. However,
this is contradictory to the reported functionality of
these genes in immune suppression. Higher expression
of these genes causing immunosuppression should have
resulted in poor prognosis of the disease [57–60]. For
example, CTLA4 is known to be expressed by T reg cells
and activated T cells to prevent further T cell activation
and thereby causing inhibition of the anti-tumor im-
mune response [54]. Interestingly, we observed better
survivability with higher CTLA4 expression, only for the
early-stage (stages I and II) OSCC patients. A human-
ized anti-CTLA4 monoclonal antibody (ipilimumab) was
approved by the Food and Drug Administration (FDA)
for metastatic and advanced melanoma. Clinical trials
and combination trials are going on for other advance
stage cancers including prostate, bladder, and lung can-
cer. Better survivability for the early-stage OSCC pa-
tients suggests that CTLA4 might be overexpressed on
the surface of early-stage tumor cells, as have been ob-
served on cancer cell lines as well as in non-small cell
lung carcinoma [61, 62]. Binding of CTLA4 with its lig-
and on APCs triggered apoptosis of tumor cells further
inhibited tumor progression. However, better under-
standing of the tumor microenvironment can lead to
elucidation of the actual role of CTLA4 in OSCC
prognosis.
Conclusions
In summary, genome-wide DNA methylation profiling
among OSCC patients in India thus revealed a set of
differentially methylated regions, which were replicated in
60–90% patients in a separate cohort of OSCC patients.
Comparison of the observed methylation pattern with
TCGA HNSC methylation data revealed 94.6% similarities,
indicating their important role in cancer development.
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Interestingly, we also observed 5.3% probes that were
uniquely differentially methylated in Indian patients, which
might be attributed to different oral habits observed in
Indian patients. Further studies correlating methylation
pattern with different oral habits might give insights into
their role in cancer development. Gene ontology and IPA
showed enrichment of differentially methylated promoters
in immune regulation pathways including those mediated
by CTLA4 and IL9 signaling. Our study thus highlights the
finding of a distinct set of differentially methylated regions
among Indian OSCC patients as well as a strong immune
component that is regulated by methylation.
Methods
Patient selection and sample collection
After clinical inspection, patients with provisional diagno-
sis of oral squamous cell carcinoma (OSCC) were re-
cruited for the study with their written consent. Sixty-four
patients were included in the study after confirmation of
well-differentiated squamous cell carcinoma from histo-
pathological reports. The study was approved by the Insti-
tutional Ethics Committee for Human Research of Indian
Statistical Institute, Kolkata, India. Tissues from the area
of the lesion and adjoining clinically uninvolved area were
collected using incisional and 3-mm punch biopsy, re-
spectively for all 64 patients. A portion of the tissue sam-
ples were collected in RNA Later (Invitrogen) and stored
at −80 °C until processing. Another portion was fixed in
the formalin and used for histopathological evaluations.
Demographic information of the OSCC patients for
both discovery and validation cohort are presented in
Table 1 and Additional file 1: Table S1. Mean age of the
patients of discovery set was 51.37 (SD ± 14.33) (range
40–90 years), while that of validation cohort was 53.35
(SD ± 12.35) (range 27–78 years). The patient samples of
discovery and validation cohort had no significant differ-
ence of age (P value = 0.306), as calculated using the
D’Agostino-Pearson omnibus normality test. There was
no significant deviation in the distribution of males and
females among OSCC patients (P value = 0.529) in both
cohorts. Nearly 82% cases from the both cohorts had
oral habits.
Illumina Infinium HumanMethylation450K bead chip and
data analysis
DNA was isolated from the lesion and adjacent unin-
volved area using DNeasy Blood and Tissue Kit (Qiagen)
following manufacturer’s protocol. The purity and con-
centration of DNA was estimated using Nanodrop 2000
(ThermoScietific). Approximately, 500 ng of genomic
DNA from each sample was used for sodium bisulfite
conversion using the EZ DNA methylation Gold Kit
(Zymo Research, USA) following the manufacturer’s
standard protocol. Genome-wide DNA methylation was
assessed using the Illumina Infinium HumanMethyla-
tion450 BeadChip (Illumina Inc, USA) according to
manufacturer’s instructions. Ten paired and one un-
paired DNA samples were subjected to Infinium
HumanMethylation450K bead chip analysis to interro-
gate 485,577 methylation sites per sample at single-
nucleotide resolution. The array data (.IDAT files) was
analyzed using RnBeads package in R for deriving the
methylation level [63]. The methylation status of all the
probes was denoted as β value, which is the ratio of the
methylated probe intensity to the overall probe intensity
(sum of methylated and unmethylated probe intensities
plus constant α, where α = 100). CpG sites having |Δβ|
≥0.20 (in OSCC vs adjacent normal) and adjusted P
value ≤0.05 was considered as differentially methylated
site. A CpG was considered hypermethylated if Δβ ≥0.20
or hypomethylated if Δβ ≤−0.20. Average β value of pro-
moters and CpG islands were compared between disease
and normal. Promoters and CGIs with |Δβ| ≥0.20 and
adjusted P value ≤0.05 were considered for further ana-
lysis. Heatmaps were generated using gplots package in
R. The data has been submitted to the Gene Expression
Omnibus (GEO) with accession number GSE87053.
HPV determination by PCR
Presence of integrated HPV sequences was detected
from DNA isolated from diseased tissue by PCR with
primers specific for the conserved L1 region of viral gen-
ome using the method as described previously [64].
Comparison with TCGA methylation data
The methylation data of our study were compared with
a publically available, open access methylation dataset
of HNSC from The Cancer Genome Atlas (TCGA)
(https://tcga-data.nci.nih.gov/docs/publications/tcga/?). In
order to ensure equivalent comparisons, TCGA samples
with malignancies at the larynx, alveolar ridge, oropharynx,
hypopharynx, and tonsil were not included in this study
(Additional file 3: Table S2). RnBeads package was used for
analysis of TCGA samples. The differentially methylated
probes, promoters and CpG islands observed in our
samples were compared with the TCGA samples.
Identification of common and unique probes
The total hypomethylated probes were categorized into
two categories viz common and unique. All stages (S1–S4)
of TCGA data were compared with OSCC disease samples.
The unique probes were significantly different
(adjusted P value ≤0.05) from each stages of TCGA
samples. Those DMPs that were similar (i.e., not
significantly different) to any stages of the TCGA
samples were considered as common hypo- or hyper-
methylated probes.
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Bisulfite sequencing PCR and quantitative real-time PCR
for methylation analysis
The bisulfite sequencing PCR (BSP) were carried out for
14 promoters by bisulfite conversion-specific primers
(Additional file 5: Table S5) designed using MethPrimer
[65]. The BSP products were analyzed on 1% agarose
gel. A part of BSP products were then used for the quan-
titative real-time methylation-specific PCR (qMSP). The
qMSP reactions were carried out using methylation-
specific primers (Additional file 5: Table S5) with
FastStart Universal SYBR Green Master Mix (Rox)
(Roche, Switzerland) in a 7900HT Fast Real-Time PCR
System Instrument (ABI, USA).
BSP cloning and sequencing
The BSP products were then selected for cloning and se-
quencing. Another part of the BSP products was purified
with the MiniElute Gel extraction Kit (Qiagen Inc.,
USA). About 165 ng of the purified BSP product was li-
gated in the TA vector (PTZ57R/T) using T4 DNA
Ligase (Takara Bio Inc., Japan). The ligated product were
then transformed into E.coliDH5α cells and plated on
LA-Ampicillin plates. The probable positive clones were
verified by colony PCR using universal M13 forward and
reverse primer and under standard conditions. The posi-
tive clones were then sequenced in 3100 Genetic
Analyzer (ABI, USA). The status of methylation of each
clone were analyzed from the chromatogram thus ob-
tained, and the percentage methylation was calculated.
Gene expression study
Twenty paired tissue samples were selected for ex-
pression analysis of the identified genes with differen-
tially methylated promoters. Biopsy samples stored in
RNA Later Solution (Invitrogen, USA) at −80 °C were
used. Tissue samples were snap frozen in liquid nitro-
gen and grinded using mortar and pestle. Total RNA
was extracted using High Pure RNA Tissue Kit
(Roche). Quality of the eluted RNA was checked in
Nanodrop spectrophotometer. Samples with low RNA
yield or impure RNA was not considered for further
study. One microgram of total RNA was used for
complementary DNA (cDNA) synthesis using Rever-
tAid First Strand cDNA Synthesis Kit (Thermo Scien-
tific). The product was subsequently diluted, and around
10 ng was finally used for each reaction. Transcripts were
quantified using specific gene expression primers (Add-
itional file 6: Table S6) in 7900HT Fast Real-Time PCR
system (Applied Biosystems) using FastStart Universal
SYBR Green Master (Rox) (Roche). All values were nor-
malized to the expression of the housekeeping gene ribo-
nuclease P (RPP30).
Survival analysis
To determine the clinical significance of the unique
hypomethylated genes, we analyzed methylation and
expression values of all 134 genes with the clinical follow
up data available at TCGA. Survival analysis for the gene
expression data were performed using OncoLnc [66]. Top
and bottom 25 percentile of expression values were
considered as high and low groups, respectively. Survival
analyses of the unique DMPs were done using the
Kaplan-Meier survival analysis in SPSS. Mantel-Cox
log-rank P value ≤0.05 was considered as significant.
The patients were sorted based on their β values for each
unique DMP. Low and high groups are generated from
the top and bottom 25 percentile patients.
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